Talecris Biotherapeutics

  Home About Talecris Therapeutic Areas Research & Development Donor to Patient Business Development Investor Relations Media Center  
About Talecris Biotherapeutics
The History of Talecris
Talecris Leadership
The Talecris Commitment
Corporate Governance & Compliance
Talecris Locations

About Talecris Biotherapeutics


Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products.


Quick Facts:

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas.

Talecris headquarters is located in the biotech hub of Research Triangle Park, N.C., USA, with additional regional headquarters in Toronto, Canada, and Frankfurt, Germany.

Talecris Plasma Resources (TPR), a wholly owned subsidiary of Talecris Biotherapeutics, is a national network of plasma collection centers that provides the source material for the production of Talecris’ critical care protein therapies.

Our primary manufacturing facility is in Clayton, N.C., USA, with additional fractionation capacity and contract manufacturing provided by our facility in Melville, N.Y.

Talecris' revenues exceeded approximately $1.4 billion in 2008.

Talecris employees, more than 4,500 worldwide, include outstanding scientists and business professionals recognized by peers, partners, patients, and professionals as passionate and committed to their work.

Talecris' Gamunex (Immune Globulin Intravenous [Human],10%) Datascapes Campaign was honored with the 2009 Medical Marketing & Media Award for the "Best Overall Advertising Campaign in the Professional Press". The MM&M Awards recognize exceptional creativity and marketing effectiveness in healthcare.

Click here for the package insert and the important safety information.

Our Clayton, N.C., facility was recently honored as an Industry Week 2007 Best Plants Finalist in recognition of its excellent performance metrics.

Between its launch in 2005 through the end of 2007, Talecris invested in excess of $550 million to support the growth of the business.

Talecris was named a "Fast 50" award winner, recognizing it as one of Research Triangle Park's fastest-growing privately held companies. The award honors privately owned businesses and their contribution to the growth and success of the entire community.

In 2007 and 2008, Talecris was included in the Companies That Care Honor Roll for a strong commitment to elevating the quality of life for their employees and for people in the broader community.

 

 

Print This Page
E-mail This Page
Talecris receives the 2009 Art of Industry Partnership award.  Read more...

Talecris Careers
Consider a Talecris Career for personal satisfaction and professional growth.
Learn More

Talecris Biotherapeutics
Contact Talecris    Glossary    Site Map
General Conditions of Use    Privacy Statement    California Compliance
© 2009 Talecris Biotherapeutics